Quintrio
Home

SERVICES-BUSINESS SERVICES, NEC

Phreesia, Inc.

PHR

Phreesia Inc is a provides an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions, enabling healthcare organizations to activate patients, streamline administrative processes, and improve financial performance across the care continuum. The group serves a diverse group of healthcare organizations, including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest, and not-for-profit and other organizations.

Last trade $12.65
Day change -$0.175 (-1.37%)
Day range $12.10 – $12.89
Volume 300,737
Market cap $796M

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$795.75M
Price / earnings
76.17×
Price / book
2.14×
Price / sales
1.57×
EV / sales
1.55×
EV / EBITDA
15.83×

Profitability

Earnings per share
$0.17
Return on assets
1.61%
Return on equity
2.81%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.18×
Current ratio
1.76×
Quick ratio
1.76×
Cash ratio
0.51×

Cash flow

Price / cash flow
8.71×
Price / free cash flow
9.85×
Free cash flow
$80.75M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PHR, quarterly periods
Line itemQ2 FY2027 Jul 31, 2026Q1 FY2027 Apr 30, 2026Q4 FY2026 Jan 31, 2026Q3 FY2026 Oct 31, 2025Q2 FY2026 Jul 31, 2025Q1 FY2026 Apr 30, 2025Q4 FY2025 Jan 31, 2025Q3 FY2025 Oct 31, 2024
Revenue$129.46M$130.94M$127.07M$120.33M$117.26M$115.94M$109.68M$106.8M
Cost of revenue$19.27M$17.66M$18.99M$18.34M$17.4M$16.64M$16.51M$17.85M
Gross profit$110.19M$113.28M$108.08M$102M$99.86M$99.3M$93.17M$88.95M
Selling, general and administrative$41.1M$42.57M$51.62M$41.64M$44.44M$42.45M$47.28M$49.7M
Research and development$27.57M$28.33M$30.93M$29.45M$29.27M$31.83M$29.63M$29.32M
Total operating expenses$102.58M$106.53M$113.63M$98.26M$101.36M$102.59M$100.79M$102.79M
Operating income$7.61M$6.75M-$5.56M$3.74M-$1.51M-$3.29M-$7.61M-$13.84M
Interest expense-$1.73M-$2.3M-$6.95M$0-$391K-$435K-$2.35M$0
Income before taxes$3.24M$4.72M-$10.32M$5.13M-$563K-$3.18M-$5.38M-$13.96M
Income taxes$1.32M$1.76M-$11.62M$854K-$1.22M$735K$1.01M$442K
Net income$1.92M$2.96M$1.3M$4.27M$654K-$3.91M-$6.39M-$14.4M
Net income attributable to common shareholders$1.92M$2.96M$1.3M$4.27M$654K-$3.91M-$6.39M-$14.4M
EBITDA$17.6M$16.7M$4.24M$11.33M$5.9M$3.59M-$680K-$5.43M
Basic earnings per share$0.03$0.05$0.02$0.07$0.01-$0.07-$0.11-$0.25
Diluted earnings per share$0.03$0.05$0.02$0.07$0.01-$0.07-$0.11-$0.25

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates

Dare Bioscience reported a Q3 loss of $0.18 per share, missing the consensus estimate of $0.13 loss by 38.46%. The company posted revenues of $0.05 million, missing estimates by 99.19%. DARE shares have declined 65.9% year-to-date versus the S&P 500's 10.5% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

MDxHealth SA (MDXH) Reports Q3 Loss, Misses Revenue Estimates

MDxHealth SA reported a quarterly loss of $0.16 per share, significantly worse than the consensus estimate of $0.07, and missed revenue expectations by 20.31% with $22.71 million in revenues. The stock has declined 95.9% year-to-date and received a Zacks Rank #3 (Hold) rating. The company has consistently underperformed consensus estimates over the last four quarters.

The Motley Fool

Why Phreesia Stock Got Knocked Down Today

Phreesia stock fell 6.58% after Raymond James analyst John Ransom downgraded the company from outperform to market perform. The downgrade was triggered by concerns over declining organic revenue growth that could turn negative in H2, combined with worries about AI spending pressuring EBITDA and potential budget constraints among healthcare provider customers. Despite 10% YoY revenue growth and nearly tripled profitability in Q2, the company missed earnings expectations.

The Motley Fool

Why Phreesia Stock Tumbled Today

Phreesia (PHR) stock fell 6.33% after reporting Q2 fiscal 2027 earnings that missed analyst expectations on net income despite beating revenue estimates. While the company posted strong net income growth to $1.9 million ($0.03 per share) and 10% revenue growth to $129.5 million, analysts expected $0.09 per share in earnings. The company maintained full-year guidance and highlighted new products AccessOne and ProviderConnect, but the analyst recommends holding off on investment given the modest performance and ongoing restructuring.

Zacks Investment Research

Phreesia (PHR) Q2 Earnings and Revenues Lag Estimates

Phreesia reported Q3 2026 earnings of $0.03 per share, missing consensus estimates of $0.11 by 72.73%, though revenues slightly missed expectations at $129.46M. The stock has underperformed the S&P 500 by 41.5% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market near-term.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.